AN2 Therapeutics, Inc
Price
FilingsNewest: 10-Q, Quarterly reportAug 11 →Insiders1 insider bought $11,602 in 1 open-market buy. 6 insiders sold $398,265, 8 of 22 sales on a 10b5-1 plan.→HoldersVivo Capital 8.7%Commodore Capital 8.1%Millennium 6.4%→Financing →PeersClosest companies: PRLD, IKT, BMEA→
From the filings
Figures
- Net income
- −$36.2Mlast 12 months
- Operating cash flow
- −$31.3Mlast 12 months
- Cash and equivalents
- $44.3Mat the last balance sheet
- Shares outstanding
- 36.3M shareson issue